Back to top

cell-therapy: Archive

Ekta Bagri

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.

BMYPositive Net Change MRKNegative Net Change GILDPositive Net Change

Urmimala Biswas

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.

REGNPositive Net Change ALCPositive Net Change GKOSPositive Net Change

Urmimala Biswas

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

DGXPositive Net Change NVDAPositive Net Change BTAINegative Net Change PLTRPositive Net Change TEMPositive Net Change

Zacks Equity Research

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.

AZNPositive Net Change BMRNNegative Net Change GILDPositive Net Change CORTPositive Net Change

Zacks Equity Research

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.

ANIPPositive Net Change CTMXPositive Net Change ALLOPositive Net Change ETNBPositive Net Change

Bryan Hayes

Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025

Despite a correction to begin the year, there are a few pockets of the market that are working.

GILDPositive Net Change JAZZPositive Net Change

Bryan Hayes

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

During this time of heightened market volatility, it pays to be invested in the right places.

GILDPositive Net Change

Zacks Equity Research

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty

Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.

PCRXNegative Net Change ARGXPositive Net Change IOVAPositive Net Change ETNBPositive Net Change